These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 772175)

  • 41. A double-blind trial of bromocriptine in Parkinson's disease.
    Mackenzie RA; Lance JW
    Med J Aust; 1978 Nov; 2(3 Suppl):27-8. PubMed ID: 370527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
    Rascol A; Montastruc JL; Rascol O; Senard JM
    Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract]   [Full Text] [Related]  

  • 45. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E; Dom R; Demedts M
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
    Baas H; Schneider E; Fischer PA; Japp G
    J Neural Transm; 1985; 64(1):45-54. PubMed ID: 4067602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
    Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
    Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bromocriptine combined with levodopa in Parkinson's disease.
    Gauthier G; Martins da Silva A
    Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Idiopathic parkinsonism treated with bromocriptine.
    Teychenne PF; Leigh PN; Reid JL; Calne DB; Greenacre JK; Petrie A; Bamji AN
    Lancet; 1975 Sep; 2(7933):473-6. PubMed ID: 51285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bromocriptine in the treatment of advanced Parkinsonism.
    Kristensen O; Hansen E
    Acta Neurol Scand; 1977 Sep; 56(3):274-6. PubMed ID: 333856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjunctive therapy with bromocriptine in Parkinson's disease.
    Temlett JA; Ming A; Saling M; Fritz VU; Blumenfeld A; Bilchik TR; Becker AL; Fourie PB; Reef HE
    S Afr Med J; 1990 Dec; 78(11):680-5. PubMed ID: 2251616
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesulergine in early Parkinson's disease: a double blind controlled trial.
    Dupont E; Mikkelsen B; Jakobsen J
    J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
    Fischer PA; Przuntek H; Majer M; Welzel D
    Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.